Respiratorius Overview

  • Founded
  • 1999
Founded
  • Status
  • Public
  • Stock Symbol
  • RESP
Stock Symbol
  • Share Price
  • $0.21
  • (As of Friday Closing)

Respiratorius General Information

Description

Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma. The company's development stage product pipeline includes RESP2000, RESP3000, VAL001, RESP9000, and RESP1000.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Stock Exchange
SAT
Primary Office
  • Magistratsvagen 10
  • 223 81 Lund
  • Sweden
+46 070-922 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Respiratorius Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.21 $0.08 - $0.44 $40.2M 189M 491K

Respiratorius Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 57,814 23,367 25,529 33,339
Revenue 0 0 0 0
EBITDA (453) (332) (357) (312)
Net Income (680) (534) (594) (577)
Total Assets 3,635 1,884 2,463 3,799
Total Debt 0 0 6
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Respiratorius Executive Team (1)

Name Title Board Seat Contact Info
Johan Drott President & Chief Executive Officer
To view Respiratorius’s complete executive team members history, request access »